Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270104 | 0.83 | CA2 (0.52) | CA2TP53CA1CA5ACA9 | |
| SCHEMBL13754584 | 0.81 | FFAR1 (0.53) | CA2TP53LMNACA1FFAR1 | |
| SCHEMBL29002854 | 0.81 | PTGS2 (0.50) | TP53HPGDKDM4EMAPTTDP1 | |
| SCHEMBL27945227 | 0.80 | AKR1B1 (0.48) | CA2AKR1B1LMNAGAATSHR | |
| SCHEMBL14720056 | 0.79 | SMN1; SMN2 (0.55) | LMNATSHRHSD17B10MAPTNFKB1 | |
| SCHEMBL30977974 | 0.78 | MAPT (0.56) | GAAKDM4EMAPTCYP51A1PTGS2 | |
| SCHEMBL1633999 | 0.77 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL1633998 | 0.77 | CA2 (0.60) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL13754456 | 0.77 | CA2 (0.50) | CA2CAMK2AAKR1B1LMNAGAA | |
| SCHEMBL21407450 | 0.77 | CYP1A2 (0.46) | CA2TP53LMNATSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263413-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | QURIENT CO., LTD. (KR) | 2025-08-21 | — | — | US | disclosed |
| EP-4249470-B1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS UNIV MARBURG (DE) | 2024-11-13 | — | — | EP | disclosed |
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4255909-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | Qurient Co. Ltd. (KR) | 2023-10-11 | — | — | EP | disclosed |
| EP-4249470-A1 | METHOD FOR PREPARING ALPHA-AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2023-09-27 | — | — | EP | disclosed |
| US-20220409773-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| WO-2022117504-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | QURIENT CO., LTD. (KR) | 2022-06-09 | — | — | WO | disclosed |
| EP-3613755-A1 | LYSINE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS USING MICROBIAL TRANSGLUTAMINASE | Novartis AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9359400-B2 | Site-specific chemoenzymatic protein modifications | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| CN-105593238-A | Lysine-specific chemoenzymatic protein modification using microbial transglutaminase | NOVARTIS AG | 2016-05-18 | — | — | CN | disclosed |
| CN-103429585-B | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2015-07-08 | — | — | CN | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| WO-2015006728-A2 | SITE-SPECIFIC CHEMOENZYMATIC PROTEIN MODIFICATIONS | USERA AIMEE (US) | 2015-01-15 | — | — | WO | disclosed |
| CN-103429585-A | Indazolyl triazole derivatives as interleukin-1 receptor associated kinase inhibitors | MERCK SERONO SA | 2013-12-04 | — | — | CN | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2009105746-A2 | TRIAZOLES AND PROCESSES FOR PRODUCING THE SAME | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263413-A1 | COMPOUNDS HAVING CYCLIN-DEPENDENT KINASE(CDK)-INHIBITORY FUNCTION | CDK1, CDK2, CCNI | CA2 3708/4885CAMK2A 402/4885AKR1B1 2458/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | CA2 3377/4885CAMK2A 1196/4885AKR1B1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.